(Q50749619)

18 March 2018

title

Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. (English)

1 reference

18 March 2018

secondary progressive multiple sclerosis

main subject

0 references

0 references

1 reference

3

Franz Fazekas

1 reference

PubMed ID

15451222

18 March 2018

Per Soelberg Sørensen

2

object named as

Per S Sørensen

1 reference

18 March 2018

Otto R Hommes

1

1 reference

18 March 2018

Monika Maas Enriquez

4

1 reference

18 March 2018

Hans W Koelmel

5

1 reference

18 March 2018

Oscar Fernandez

6

1 reference

18 March 2018

Carlo Pozzilli

7

1 reference

18 March 2018

Paul O'Connor

8

1 reference

18 March 2018

language of work or name

English

0 references

publication date

1 September 2004

1 reference

18 March 2018

published in

The Lancet

1 reference

18 March 2018

volume

364

1 reference

18 March 2018

issue

9440

1 reference

18 March 2018

page(s)

1149-1156

1 reference

18 March 2018

First results of immunotherapy with immunoglobulin G in multiple sclerosis patients

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Meta-analysis of the placebo-treated groups in clinical trials of progressive MS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917101-8

7 January 2021

10.1016/S0140-6736(04)17101-8

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/e5pgst5tpfczjdebl6omyp3tpy

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_e5pgst5tpfczjdebl6omyp3tpy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/e5pgst5tpfczjdebl6omyp3tpy

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/e5pgst5tpfczjdebl6omyp3tpy

30 July 2022